The ESTRO Breur Lecture 2010: Toward a tailored patient approach in rectal cancer

Radiotherapy and Oncology

Volumn 100, Issue 1, 2011, Pages 15-21

  Haustermans, Karin ^a   Debucquoy, Annelies ^a   Lambrecht, Maarten ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biomarkers; Functional imaging; Molecular targeted agents; Rectal cancer

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; PANITUMUMAB; VASCULOTROPIN INHIBITOR;

CHEMORADIOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECTUM CANCER; RECTUM SURGERY; REVIEW; TREATMENT RESPONSE;

CHEMORADIOTHERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; PERSONAL HEALTH SERVICES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051800811     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.05.024     Document Type: Review

References (122)

1. R.J. Heald, and R.D. Ryall Recurrence and survival after total mesorectal excision for rectal cancer Lancet 1 1986 1479 1482 (Pubitemid 16095660)
2. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985;312(23):1465- 72.
3. J. Folkesson, H. Birgisson, and L. Pahlman Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate J Clin Oncol 23 2005 5644 5650
4. D. Sebag-Montefiore, R.J. Stephens, and R. Steele Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial Lancet 373 2009 811 820
5. E. Kapiteijn, C.A. Marijnen, and I.D. Nagtegaal Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638 646
6. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
7. K. Bujko, M.P. Nowacki, and A. Nasierowska-Guttmejer Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 2006 1215 1223 (Pubitemid 44547018)
8. J.P. Gerard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 2006 4620 4625 (Pubitemid 46630960)
9. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123 (Pubitemid 44394918)
10. K. Bujko, M.P. Nowacki, and A. Nasierowska-Guttmejer Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy Radiother Oncol 72 2004 15 24 (Pubitemid 38952855)
11. L. Pietrzak, K. Bujko, and M.P. Nowacki Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial Radiother Oncol 84 2007 217 225 (Pubitemid 47362404)
12. C. Radu, A. Berglund, L. Pahlman, and B. Glimelius Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study Radiother Oncol 87 2008 343 349
13. A. Gerard, M. Buyse, and B. Nordlinger Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Ann Surg 208 1988 606 614 (Pubitemid 18267703)
14. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 1990;66(1):49-55.
15. P.A. Goldberg, R.J. Nicholls, N.H. Porter, S. Love, and J.E. Grimsey Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure Eur J Cancer 30A 1994 1602 1606 (Pubitemid 24355472)
16. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
17. J.A. Reis Neto, F.A. Quilici, and J.A. Reis Jr A comparison of nonoperative vs. preoperative radiotherapy in rectal carcinoma. A 10-year randomized trial Dis Colon Rectum 32 1989 702 710 (Pubitemid 19196872)
18. O. Dahl, A. Horn, and I. Morild Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway Cancer 66 1990 2286 2294
19. P.J. Marsh, R.D. James, and P.F. Schofield Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial Dis Colon Rectum 37 1994 1205 1214
20. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996;348:1605-10.
21. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
22. D. Sebag-Montefiore, K. Bujko, and V. Valentini Rectal cancer multidisciplinary management: evidences and future landscape Radiother Oncol 92 2009 145 147
23. V. Valentini, B. Glimelius, and B.D. Minsky The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus Radiother Oncol 76 2005 241 250 (Pubitemid 41394273)
24. V. Valentini, R. Beets-Tan, and J.M. Borras Evidence and research in rectal cancer Radiother Oncol 87 2008 449 474
25. V. Valentini, C. Aristei, and B. Glimelius Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2) Radiother Oncol 92 2009 148 163
26. R.J. Stephens, L.C. Thompson, and P. Quirke Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial J Clin Oncol 28 2010 4233 4239
27. J.M. Robertson, D. Lockman, D. Yan, and M. Wallace The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer Int J Radiat Oncol Biol Phys 70 2008 413 418
28. B.D. Minsky, J.A. Conti, Y. Huang, and K. Knopf Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer J Clin Oncol 13 1995 1409 1416
29. C.A. Marijnen, E. Kapiteijn, and C.J. van de Velde Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial J Clin Oncol 20 2002 817 825 (Pubitemid 34111391)
30. S.T. Peeters, M.S. Hoogeman, and W.D. Heemsbergen Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 63 2005 1142 1152 (Pubitemid 41505294)
31. I.J. Das, R.M. Lanciano, B. Movsas, K. Kagawa, and S.J. Barnes Efficacy of a belly board device with CT-simulation in reducing small bowel volume within pelvic irradiation fields Int J Radiat Oncol Biol Phys 39 1997 67 76 (Pubitemid 27396283)
32. B. Engels, R.M. De, and K. Tournel Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel Int J Radiat Oncol Biol Phys 74 2009 1476 1480
33. S. Roels, W. Duthoy, and K. Haustermans Definition and delineation of the clinical target volume for rectal cancer Int J Radiat Oncol Biol Phys 65 2006 1129 1142
34. J.P. Gerard, O. Chapet, and C. Nemoz Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial J Clin Oncol 22 2004 2404 2409 (Pubitemid 41115397)
35. A. Habr-Gama, R.O. Perez, and W. Nadalin Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results Ann Surg 240 2004 711 717
36. A. Debucquoy, and K. Haustermans How might knowledge of the molecular biology of rectal cancer aid us in deciding treatment? Curr Colorectal Cancer Rep 6 2010 221 227
37. N. Smith, and G. Brown Preoperative staging of rectal cancer Acta Oncol 47 2008 20 31
38. A. Chiti, M. Kirienko, and V. Gregoire Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol 96 2010 277 279
39. C. Capirci, D. Rubello, and F. Chierichetti Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy AJR Am J Roentgenol 187 2006 W202 W208
40. C. Capirci, L. Rampin, and P.A. Erba Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy Eur J Nucl Med Mol Imaging 34 2007 1583 1593 (Pubitemid 47476915)
41. V. Valentini, C. Coco, and N. Cellini Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation Int J Radiat Oncol Biol Phys 45 1999 1175 1184
42. R.F. Vliegen, R.G. Beets-Tan, and B. Vanhauten Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer? Strahlenther Onkol 184 2008 457 464
43. M. Maas, P.J. Nelemans, and V. Valentini Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 2010 835 844
44. F.M. Vecchio, V. Valentini, and B.D. Minsky The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer Int J Radiat Oncol Biol Phys 62 2005 752 760 (Pubitemid 40779765)
45. A. Habr-Gama, R.O. Perez, and W. Nadalin Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival J Gastrointest Surg 9 2005 90 99
46. B. Barbaro, C. Fiorucci, and C. Tebala Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy Radiology 250 2009 730 739
47. M.E. Juweid, and B.D. Cheson Positron-emission tomography and assessment of cancer therapy N Engl J Med 354 2006 496 507 (Pubitemid 43200300)
48. D.M. Koh, and D.J. Collins Diffusion-weighted MRI in the body: applications and challenges in oncology AJR Am J Roentgenol 188 2007 1622 1635 (Pubitemid 46866868)
49. C. Capirci, D. Rubello, and F. Chierichetti Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET Biomed Pharmacother 58 2004 451 457 (Pubitemid 39349494)
50. C. Capirci, D. Rubello, and F. Pasini The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery Int J Radiat Oncol Biol Phys 74 2009 1461 1469
51. G.L. Cascini, A. Avallone, and P. Delrio 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer J Nucl Med 47 2006 1241 1248 (Pubitemid 47544874)
52. M.H. Janssen, M.C. Ollers, and R.G. Riedl Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging Int J Radiat Oncol Biol Phys 77 2010 392 399
53. M.H. Janssen, M.C. Ollers, and R.G. van Stiphout Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings Radiother Oncol 94 2010 151 155
54. M. Lambrecht, C. Deroose, and S. Roels The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer Acta Oncol 49 2010 956 963
55. D. Mak, D.L. Joon, and M. Chao The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer Radiother Oncol 97 2010 205 211
56. R. Rosenberg, K. Herrmann, and R. Gertler The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT Int J Colorectal Dis 24 2009 191 200
57. M.S. Yoon, S.J. Ahn, and B.S. Nah The metabolic response using (1)F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer Radiother Oncol 98 2011 134 138
58. M.H. Janssen, M.C. Ollers, and R.G. van Stiphout PET-based treatment response evaluation in rectal cancer: prediction and validation Int J Radiat Oncol Biol Phys 2011 10.1016/j.ijrobp.2010.11.038
59. R.G. van Stiphout, G. Lammering, and J. Buijsen Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging Radiother Oncol 98 2011 126 133
60. V. Vandecaveye, F. De Keyzer, and S. Nuyts Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings Int J Radiat Oncol Biol Phys 67 2007 960 971
61. A.A. Abdel Razek, A.Y. Kandeel, and N. Soliman Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes AJNR Am J Neuroradiol 28 2007 1146 1152 (Pubitemid 46984559)
62. A. Dzik-Jurasz, C. Domenig, and M. George Diffusion MRI for prediction of response of rectal cancer to chemoradiation Lancet 360 2002 307 308 (Pubitemid 34874724)
63. M. Lambrecht, V. Vandecaveye, and F. De Keyzer Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results Int J Radiat Oncol Biol Phys 2011
64. Y.S. Sun, X.P. Zhang, and L. Tang Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging Radiology 254 2010 170 178
65. G. Majno, and I. Joris Apoptosis, oncosis, and necrosis. An overview of cell death Am J Pathol 146 1995 3 15
66. V. Vandecaveye, F. De Keyzer, and S. Nuyts Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings Int J Radiat Oncol Biol Phys 67 2007 960 971
67. M. Lambrecht, C. Deroose, and S. Roels The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer Acta Oncol 49 2010 956 963
68. A.R. Padhani, G. Liu, and D.M. Koh Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 2009 102 125
69. L. Veldeman, I. Madani, and F. Hulstaert Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies Lancet Oncol 9 2008 367 375 (Pubitemid 351411653)
70. Y. Yang, and L. Xing Towards biologically conformal radiation therapy (BCRT): selective IMRT dose escalation under the guidance of spatial biology distribution Med Phys 32 2005 1473 1484 (Pubitemid 40880538)
71. C.C. Ling, J. Humm, and S. Larson Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality Int J Radiat Oncol Biol Phys 47 2000 551 560 (Pubitemid 30317470)
72. U. Nestle, W. Weber, M. Hentschel, and A.L. Grosu Biological imaging in radiation therapy: role of positron emission tomography Phys Med Biol 54 2009 R1 R25
73. A. van Barrdwick, B.G. Baumert, and G. Bosmans The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning Cancer Treat Rev 32 2006 245 260 (Pubitemid 44502002)
74. K.S. Chao, W.R. Bosch, and S. Mutic A novel approach to overcome hypoxic tumor resistance. Cu-ATSM-guided intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 49 2001 1171 1182 (Pubitemid 32184623)
75. D. Thorwarth, S.M. Eschmann, F. Paulsen, and M. Alber Hypoxia dose painting by numbers: a planning study Int J Radiat Oncol Biol Phys 68 2007 291 300 (Pubitemid 46589864)
76. M. Lambrecht, and K. Haustermans Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors Radiother Oncol 96 2010 339 346
77. S. Roels, P. Slagmolen, and J. Nuyts Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol 47 2008 1237 1248
78. D.A. Patel, S.T. Chang, and K.A. Goodman Impact of integrated PET/CT on variability of target volume delineation in rectal cancer Technol Cancer Res Treat 6 2007 31 36 (Pubitemid 46385905)
79. C.T. Muijs, J.C. Beukema, and J. Widder 18F-FLT-PET for detection of rectal cancer Radiother Oncol 98 2011 357 359
80. J. Buijsen, J. van den Bogaard, and M.H. Janssen FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer Radiother Oncol 98 2011 270 276
81. I.F. Ciernik, M. Huser, C. Burger, J.B. Davis, and G. Szekely Automated functional image-guided radiation treatment planning for rectal cancer Int J Radiat Oncol Biol Phys 62 2005 893 900 (Pubitemid 40779784)
82. S. Roels, P. Slagmolen, and J. Nuyts Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls Int J Radiat Oncol Biol Phys 75 2009 782 790
83. J. Bussink, J.H. Kaanders, and A.J. van der Kogel Microenvironmental transformations by Radiother Oncol 82 2007 10 17
84. G. Lammering Molecular predictor and promising target: will EGFR now become a star in radiotherapy? Radiother Oncol 74 2005 89 91 (Pubitemid 40331864)
85. R.E. Meyn, A. Munshi, J.V. Haymach, L. Milas, and K.K. Ang Receptor signaling as a regulatory mechanism of DNA repair Radiother Oncol 92 2009 316 322
86. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137 (Pubitemid 33674041)
87. I. Uberall, Z. Kolar, R. Trojanec, J. Berkovcova, and M. Hajduch The status and role of ErbB receptors in human cancer Exp Mol Pathol 84 2008 79 89
88. J.P. Spano, C. Lagorce, and D. Atlan Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol 16 2005 102 108 (Pubitemid 40124486)
89. T.D. Barber, B. Vogelstein, K.W. Kinzler, and V.E. Velculescu Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 351 2004 2883 (Pubitemid 40051921)
90. K.L. Spindler, J. Lindebjerg, and J.N. Nielsen Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods Int J Oncol 29 2006 1159 1165
91. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578 (Pubitemid 43209104)
92. M. Baumann, and M. Krause Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 2004 257 266 (Pubitemid 39265378)
93. M. Baumann, M. Krause, and E. Dikomey EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms Radiother Oncol 83 2007 238 248 (Pubitemid 46915540)
94. A. Debucquoy, J.P. Machiels, W.H. McBride, and K. Haustermans Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation Clin Cancer Res 16 2010 2709 2714
95. K. Horisberger, A. Treschl, and S. Mai Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial Int J Radiat Oncol Biol Phys 2009
96. J.P. Machiels, C. Sempoux, and P. Scalliet Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann Oncol 18 2007 738 744 (Pubitemid 46523279)
97. C. Rodel, D. Arnold, and M. Hipp Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer Int J Radiat Oncol Biol Phys 70 2008 1081 1086 (Pubitemid 351296110)
98. C. Rodel, T. Liersch, and R.M. Hermann Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer J Clin Oncol 25 2007 110 117 (Pubitemid 350003058)
99. A. Debucquoy, K. Haustermans, and A. Daemen Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer J Clin Oncol 27 2009 2751 2757
100. B. Rau, I. Sturm, and H. Lage Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy J Clin Oncol 21 2003 3391 3401 (Pubitemid 46594071)
101. C. Rodel, G.G. Grabenbauer, and T. Papadopoulos Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer Int J Radiat Oncol Biol Phys 52 2002 294 303 (Pubitemid 34172996)
102. P. Carmeliet VEGF as a key mediator of angiogenesis in cancer Oncology 69 2005 4 10 (Pubitemid 41680947)
103. J.C. Lee, N.H. Chow, S.T. Wang, and S.M. Huang Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients Eur J Cancer 36 2000 748 753
104. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676 (Pubitemid 36749215)
105. D. Shweiki, A. Itin, D. Soffer, and E. Keshet Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843 845
106. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 2003 401 410 (Pubitemid 37328844)
107. J.H. Harmey, and D. Bouchier-Hayes Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy Bioessays 24 2002 280 283 (Pubitemid 34248694)
108. R.S. Warren, H. Yuan, M.R. Matli, N.A. Gillett, and N. Ferrara Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis J Clin Invest 95 1995 1789 1797
109. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
110. C.G. Willett, S.V. Kozin, and D.G. Duda Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice Semin Oncol 33 2006 S35 S40
111. R.T. Tong, Y. Boucher, and S.V. Kozin Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736 (Pubitemid 38697278)
112. H. Wildiers, G. Guetens, and B.G. De Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 Br J Cancer 88 2003 1979 1986 (Pubitemid 36829677)
113. F. Winkler, S.V. Kozin, and R.T. Tong Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563 (Pubitemid 40017699)
114. D. Lambrechts, E. Storkebaum, and M. Morimoto VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death Nat Genet 34 2003 383 394 (Pubitemid 36935331)
115. J.M. Ebos, C.R. Lee, and W. Cruz-Munoz Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
116. M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
117. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
118. R.S. Kerbel, J. Yu, and J. Tran Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches Cancer Metastasis Rev 20 2001 79 86 (Pubitemid 34074682)
119. K.D. Miller, C.J. Sweeney, and G.W. Sledge Jr. Can tumor angiogenesis be inhibited without resistance? EXS 2005 95 112
120. H.J. Burstein, A.D. Elias, and H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
121. M.R. Mancuso, R. Davis, and S.M. Norberg Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621 (Pubitemid 44511625)
122. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)